QurAlis NEWS

QurAlis Announces Agreement to Strengthen ALS Pipeline

July 1, 2020

QurAlis to in-license lead excitotoxicity targeted ALS therapeutic candidates from Lilly Cambridge, MA, July 01, 2020 — QurAlis Corporation, a biotech company focused on developing precision medicines for amyotrophic lateral…

Read More

QurAlis raises $42 Million Series A Financing to Develop New Therapies for Amyotrophic Lateral Sclerosis (ALS)

May 13, 2020

CAMBRIDGE, Mass., May 13, 2020— QurAlis Corporation, a biotech company focused on developing precision therapeutics for amyotrophic lateral sclerosis (ALS) and other neurologic diseases, today announced the raise of a…

Read More

QurAlis wins the Pfizer Golden Ticket!

November 9, 2018

QurAlis has won the Pfizer Golden Ticket! to read more click here.

Read More

An Appalachian odyssey: Hunting for ALS genes along a sprawling family tree

August 7, 2018

The man had come for a third opinion. Other doctors had told him he had amyotrophic lateral sclerosis, or ALS, a neuromuscular disease that causes progressive paralysis, but he didn’t…

Read More

Discovery Advances

May 22, 2018

We successfully generated a crystal structure of one of our early lead molecules in complex with our molecular target.  This structure is currently being used to design new compounds.

Read More

QurAlis Launches with Seed Funding from MPH, Amgen and Alexandria, united in the fight to cure ALS

April 5, 2018

CAMBRIDGE, Mass., April 5, 2018. QurAlis Corporation, a new private biotech company focused on developing precision solutions to cure ALS, today announced the addition of biotech investors MP Healthcare Venture…

Read More

QurAlis has won the Amgen Golden Ticket at LabCentral

December 15, 2017

CAMBRIDGE, Mass., Dec. 15, 2017  QurAlis was chosen by an Amgen internal committee and live audience members at a “Quick Pitch” event hosted by Amgen at its Cambridge R&D and Operations…

Read More

ALS News Today


Whether you or a loved one is battling ALS and you want to be a part of our clinical trials, or you want to invest in the fight against this debilitating disease, we want to hear from you. Fill out the form below today and we will get back to you as quickly as possible.

  • This field is for validation purposes and should be left unchanged.